Advertisement

Clinical Orthopaedics and Related Research

, Volume 466, Issue 3, pp 729–736 | Cite as

Predictors of Survival in Patients With Bone Metastasis of Lung Cancer

  • Hideshi SugiuraEmail author
  • Kenji Yamada
  • Takahiko Sugiura
  • Toyoaki Hida
  • Tetsuya Mitsudomi
Original Article Tumor

Abstract

The prognosis of patients with bone metastasis from lung cancer has not been well documented. We assessed the survival rates after bone metastasis and prognostic factors in 118 patients with bone metastases from lung cancer. The cumulative survival rates after bone metastasis from lung cancer were 59.9% at 6 months, 31.6% at 1 year, and 11.3% at 2 years. The mean survival was 9.7 months (median, 7.2 months; range, 0.1–74.5 months). A favorable prognosis was more likely in women and patients with adenocarcinoma, solitary bone metastasis, no metastases to the appendicular bone, no pathologic fractures, performance status 1 or less, use of systemic chemotherapy, and use of an epithelial growth factor receptor inhibitor. Analyses of single and multiple variables indicated better prognoses for patients with adenocarcinoma, no evidence of appendicular bone metastases, and treatment with an epithelial growth factor receptor inhibitor. The mean survival period was longer in a small group treated with an epithelial growth factor receptor inhibitor than in the larger untreated group. The data preliminarily suggest treatment with an epithelial growth factor receptor inhibitor may improve survival after bone metastasis.

Level of Evidence: Level IV, prognostic study. See the Guidelines for Authors for a complete description of levels of evidence.

Keywords

Lung Cancer Bone Metastasis Gefitinib Pathologic Fracture Cumulative Survival Rate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

We thank Mitsuko Yokouchi and Kiyonori Kuriki for statistical assistance and Shoko Miyachi for administrative assistance in the preparation of this manuscript.

References

  1. 1.
    Agarwala AK, Hanna NH. Long-term survival in a patient with stage IV non-small-cell lung carcinoma after bone metastasectomy. Clin Lung Cancer. 2005;6:367–368.PubMedGoogle Scholar
  2. 2.
    Ando M, Ando Y, Sugiura S, Minami H, Saka H, Sakai S, Shimokata K, Hasegawa Y. Prognostic factors for short-term survival in patients with stage IV non-small cell lung cancer. Jpn J Cancer Res. 1999;90:249–253.PubMedGoogle Scholar
  3. 3.
    Batson OV. The function of vertebral veins and their role in spread of metastases. Ann Surg. 1940;112:138–149.PubMedCrossRefGoogle Scholar
  4. 4.
    Freise G, Gabler A, Liebig S. Bronchial carcinoma and long-term survival: retrospective study of 433 patients who underwent resection. Thorax. 1978;33:228–234.PubMedCrossRefGoogle Scholar
  5. 5.
    Hansen BH, Keller J, Laitinen M, Berg P, Skjeldal S, Trovik C, Nilsson J, Walloe A, Kalén A, Wedin R. The Scandinavian Sarcoma Group Skeletal Metastasis Register. Survival after surgery for bone metastases in the pelvis and extremities. Acta Orthop Scand Suppl. 2004;75:11–15.PubMedCrossRefGoogle Scholar
  6. 6.
    Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, Rojo F, Hong WK, Swaisland H, Averbuch SD, Ochs J, LoRusso PM. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol. 2002;20:3815–3825.PubMedCrossRefGoogle Scholar
  7. 7.
    Hirano Y, Oda M, Tsunezuka Y, Ishikawa N, Watanabe G. Long-term survival cases of lung cancer presented as solitary bone metastasis. Ann Thorac Cardiovasc Surg. 2005;11:401–404.PubMedGoogle Scholar
  8. 8.
    Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, Ebina M, Kikuchi T, Moriya T, Nukiwa T. Severe acute interstitial pneumonia and gefitinib. Lancet. 2003;361:137–139.PubMedCrossRefGoogle Scholar
  9. 9.
    Johnston AD. Pathology of metastatic tumors in bone. Clin Orthop Relat Res. 1970;73:8–32.PubMedCrossRefGoogle Scholar
  10. 10.
    Katagiri H, Takahashi M, Wakai K, Sugiura H, Kataoka T, Nakanishi K. Prognostic factors and a scoring system for patients with skeletal metastasis. J Bone Joint Surg Br. 2005;87:698–703.PubMedCrossRefGoogle Scholar
  11. 11.
    Matsuyama W, Yamamoto M, Machida K, Mitsuyama H, Watanabe M, Higashimoto I, Osame M, Arimura K. [Two lung adenocarcinoma patients with multiple brain metastasis treated with gefitinib and surviving more than 2 years] (in Japanese). Nihon Kokyuki Gakkai Zasshi. 2006;44:653–658.PubMedGoogle Scholar
  12. 12.
    Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, Hatooka S, Shinoda M, Takahashi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol. 2005;23:2513–2520.PubMedCrossRefGoogle Scholar
  13. 13.
    Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997;111:1710–1717PubMedCrossRefGoogle Scholar
  14. 14.
    Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–655.PubMedCrossRefGoogle Scholar
  15. 15.
    Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst. 1980;65:25–32.PubMedGoogle Scholar
  16. 16.
    Tofe AJ, Francis MD, Harvey WJ. Correlation of neoplasms with incidence and localization of skeletal metastases: an analysis of 1,355 diphosphonate bone scans. J Nucl Med. 1975;16:986–989.PubMedGoogle Scholar
  17. 17.
    Tokuhashi Y, Matsuzaki H, Toriyama S, Kawano H, Ohsaka S. Scoring system for the preoperative evaluation of metastatic spine tumor prognosis. Spine. 1990;15:1110–1113.PubMedCrossRefGoogle Scholar
  18. 18.
    Tomita K, Kawahara N, Baba H, Tsuchiya H, Nagata S, Toribatake Y. Total en bloc spondylectomy for solitary spinal metastases. Int Orthop. 1994;18:291–298.PubMedCrossRefGoogle Scholar
  19. 19.
    Tomita K, Kawahara N, Kobayashi T, Yoshida A, Murakami H, Akamaru T. Surgical strategy for spinal metastases. Spine. 2001;26:298–306.PubMedCrossRefGoogle Scholar
  20. 20.
    van der Linden YM, Dijkstra SP, Vonk EJ, Marijnen CA, Leer JW. Dutch Bone Metastasis Study Group. Prediction of survival in patients with metastases in the spinal column: results based on a randomized trial of radiotherapy. Cancer. 2005;103:320–328.PubMedCrossRefGoogle Scholar
  21. 21.
    Yokouchi H, Yamazaki K, Kinoshita I, Konishi J, Asahina H, Sukoh N, Harada M, Akie K, Ogura S, Ishida T, Munakata M, Dosaka-Akita H, Isobe H, Nishimura M. Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer. BMC Cancer. 2007;7:51.PubMedCrossRefGoogle Scholar

Copyright information

© The Association of Bone and Joint Surgeons 2008

Authors and Affiliations

  • Hideshi Sugiura
    • 1
    Email author
  • Kenji Yamada
    • 1
  • Takahiko Sugiura
    • 2
  • Toyoaki Hida
    • 3
  • Tetsuya Mitsudomi
    • 4
  1. 1.Department of Orthopaedic SurgeryAichi Cancer CenterChikusa-kuJapan
  2. 2.Department of Respiratory DiseaseAichi Circulation and Respiratory CenterNagoya CityJapan
  3. 3.Department of Respiratory DiseaseAichi Cancer CenterNagoya CityJapan
  4. 4.Department of Thoracic SurgeryAichi Cancer CenterNagoya CityJapan

Personalised recommendations